Bo Shen/iStock via Getty Images XBiotech Inc. ( NASDAQ: XBIT ) has been able to complete recruitment for a few studies already, and it has initiated another one targeting patients with Rheumatoid arthritis [RA]. Natrunix is being developed to treat patients with RA and pancreatic cancer.
Hutrukin is being advanced to help patients with stroke. The premise of this biotech between both of these candidates is to use the body's natural immune response to inflammation, without any modification of an antibody. Thus, this has a technology platform known as True HumanTM antibodies.
It believes this approach will result in not only improved efficacy for patients, but a far more tolerable treatment option compared to the rest. Having said that, it remains to be seen whether the studies above prove the concept of True Human antibodies. Still, with the completion of enrollment of a few studies, plus the initiation of another in RA, I believe that it remains a hold.
True Human Antibodies Platform Technology Could Change Scope Of Treatment In terms of the most recent clinical development from its pipeline, it completed enrollment of its randomized, open-label, placebo-controlled phase 1 dose-escalation study. The purpose of this study is to see if Hutrukin can reduce brain injury after a person has an ischemic stroke. Ischemic stroke occurs when there is a loss of blood flowing into a portion of the brain, which in turn results in cell death.
Then what is the goal of Hutrukin? Where this d.
